Topic: Canadian biomanufacturing

The Short Report – May 19, 2021: Ottawa injects $200 million into domestic vaccine manufacturing capacity, CAN Health Network project extended, nuclear leaders prepare CANDU reactors for decommissioning, and more

Resilience Biotechnologies receives significant funding to produce made-in-Canada vaccines, Ottawa extends the CAN Health Network project in Ontario by one year with a $3.25-million investment, Canada’s nuclear leaders collaborate on the decommissioning process, and more.

Feds invest $887 million to ensure reliable vaccine supply for COVID-19, other pandemics

The federal government’s investment of $887 million make Canada self-sufficient in manufacturing vaccines against COVID-19 and future pandemics, say medical and other experts. Along with Canadian-led vaccine development, Ottawa is investing in a network of small-scale vaccine manufacturing facilities that together will be able to produce enough vaccine for Canada’s population during pandemics.